Targeted protein degradation is reshaping drug discovery by turning “undruggable” proteins into tractable therapeutic targets.
Targeted protein degradation is reshaping drug discovery by turning “undruggable” proteins into tractable therapeutic targets.Technologies like PROTACs and molecular glues harness the cell’s own protein clearance machinery to remove disease-causing proteins rather than merely inhibiting them.
This shift from occupancy-driven pharmacology to event-driven pharmacology opens new possibilities across oncology, neurodegeneration, and immune disorders.
Why targeted protein degradation matters
Traditional small molecules usually block active sites or modulate protein function through sustained binding.
Many disease-relevant proteins lack suitable pockets for small-molecule inhibition, or require sustained exposure that can drive toxicity. PROTACs (proteolysis-targeting chimeras) and molecular glues work differently: they recruit an E3 ubiquitin ligase to the target protein, triggering ubiquitination and proteasomal degradation. That catalytic mode of action means lower doses can have prolonged effects, potentially improving selectivity and reducing off-target activity.
Key advantages include:
– Ability to target scaffolding or transcriptional proteins with no enzymatic pocket
– Potential for more durable pharmacodynamic responses with intermittent dosing
– Opportunities to overcome resistance driven by target overexpression or mutation
Major challenges in discovery and development
Despite promising biology, several drug discovery hurdles remain. Designing molecules that are cell-permeable, metabolically stable, and able to form productive ternary complexes with both the target and an E3 ligase is nontrivial. Oral bioavailability is a particular challenge because degrader molecules are often larger and more polar than traditional small molecules. Off-target degradation and degradation of protein complexes raise safety concerns that require careful proteome-wide profiling.
Selecting an appropriate E3 ligase is another active area of work.
The most commonly used ligases may not be expressed in all tissues or disease states, so expanding the repertoire of recruitable ligases and discovering tissue-selective ligase ligands are priorities. Resistance mechanisms—such as mutations in the ligase, loss of ligase expression, or changes in ubiquitin pathway components—also require monitoring and contingency planning.
Tools accelerating discovery
Chemical biology tools and advanced screening methods are accelerating progress. High-throughput cellular assays that detect target destruction, proteomics that map degradation profiles, and structural biology that reveals ternary complex interfaces help optimize potency and selectivity. Organoid models and microphysiological systems give earlier insight into tissue-specific effects and toxicity, improving translational predictability. Covalent ligands, light-activated degraders, and antibody-drug conjugate-style delivery are expanding the modality toolbox, offering ways to improve selectivity and control.
Clinical and translational outlook
Targeted protein degradation is progressing through clinical evaluation across multiple therapeutic areas.
Early clinical data suggest the approach can achieve target knockdown with manageable safety profiles for some targets, validating the concept. Combination strategies—pairing degraders with immune therapies or pathway inhibitors—are a logical next step to deepen responses and delay resistance.
Practical considerations for teams
– Prioritize early assessment of physicochemical properties to improve oral exposure
– Use unbiased proteomics to profile on- and off-target degradation
– Map E3 ligase expression across disease-relevant tissues before committing to a ligase-recruiting strategy
– Design contingency plans for likely resistance mechanisms
Targeted protein degradation represents a paradigm shift that complements rather than replaces traditional drugs. With continued innovation in chemistry, biology, and translational models, degraders offer a powerful route to drugging challenging targets and expanding therapeutic opportunities across many diseases.